Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction
Key result
Post-thrombolysis thrombocytopenia affects ~16% of AMI patients and is linked to excess hemorrhage and mortality.
- n=1,001
Why the study?
Hemorrhage remains a major complication of thrombolytic therapy for acute myocardial infarction, and thrombocytopenia may be associated with this bleeding risk.
Population
1,001 acute myocardial infarction patients receiving thrombolytic therapy
Comparison
Patients with thrombocytopenia vs patients without thrombocytopenia
Design
Cohort study (pooled trial population analysis)
Follow-up
In-hospital
Authors
Discussion
Loading...
Member takes
Implication
Clinical trial analysis demonstrates higher bleeding and in-hospital mortality with post-thrombolytic thrombocytopenia in myocardial infarction, suggesting a need for daily platelet monitoring.
Key Points
- To examine the incidence and clinical consequences of in-hospital thrombocytopenia following thrombolytic therapy for acute myocardial infarction.
- Evaluated 1,001 patients enrolled in Phases 2, 3, and 5 of the TAMI trial and the urokinase trial who received recombinant tissue-type plasminogen activator, urokinase, or combination therapy alongside heparin, aspirin, and calcium-channel blockers.
- Defined thrombocytopenia as a nadir platelet count < 100,000/µL or < 50% of baseline, and evaluated its independent association with in-hospital mortality using multivariable logistic regression.
- Thrombocytopenia developed in 16.4% of patients, with incidence rates consistent across the different thrombolytic drug regimens.
- Patients with thrombocytopenia presented with lower median acute ejection fractions, an increased prevalence of three-vessel coronary disease, and higher blood loss indices.
- In-hospital mortality was significantly higher in patients with thrombocytopenia, persisting as an independent predictor after multivariable adjustment for age, acute ejection fraction, multi-vessel disease, bypass surgery, and intra-aortic balloon counterpulsation.
Study Design
Type
Cohort (n=1,001)
PICO
P
Population
1,001 patients with acute myocardial infarction who received thrombolytic therapy, evaluated for in-hospital thrombocytopenia.
E
Exposure / Comparator
Thrombocytopenia vs No thrombocytopenia
O
Primary Outcome
In-hospital mortality and hemorrhage
Cite This Study
Harrington et al. (1994) conducted a cohort in acute myocardial infarction (n=1,001). Thrombocytopenia vs. No thrombocytopenia was evaluated on In-hospital mortality and hemorrhage. In-hospital thrombocytopenia occurred in 16.4% of patients receiving thrombolytic therapy for acute myocardial infarction and was associated with excess hemorrhage and mortality.